Company news
AstraZeneca PLC news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
FDA accepts durvalumab for BLA in bladder cancer
December 9, 2016
Tagrisso data shows superiority over chemotherapy
December 6, 2016
AZ completes agreement for Rhinocort Aqua rights
December 5, 2016
AZ head and neck cancer trials resume enrolment
November 22, 2016
AZ out-licensing deal with Allergan completed
November 17, 2016
Year-To-Date and Q3 2016 Results
November 10, 2016
Dealing by Person Closely Associated
November 1, 2016
AZ completes US Aralez agreement for Toprol-XL
October 31, 2016
AstraZeneca Head and Neck Cancer Trials
October 27, 2016
Positive results in AstraZeneca Lynparza trial
October 26, 2016
FDA accepts for review ZS-9 NDA for hyperkalaemia
October 18, 2016
Az divests rights to Rhinocort Aqua outside US
October 7, 2016
AZ agreement with Aralez for Toprol-XL in US
October 4, 2016
AstraZeneca reports top-line EUCLID results in PAD
October 4, 2016
MedImmune out-licenses medicine to Allergan
October 3, 2016
Change to AstraZeneca board of directors
September 28, 2016
Calls
The 5 newest of 16 calls. Every call is listed under its year.
- AstraZeneca (LSE:AZN) Q2 2026 Earnings Call
Jul 27, 2026
Transcript - AstraZeneca (LSE:AZN) Q1 2026 Earnings Call
Apr 29, 2026
Transcript - AstraZeneca (LSE:AZN) Q4 2025 Earnings Call
Feb 10, 2026
Transcript - AstraZeneca (LSE:AZN) Q3 2025 Earnings Call
Nov 11, 2025
Transcript - AstraZeneca (LSE:AZN) Q2 2025 Earnings Call
Jul 29, 2025
Transcript
Decks
The 5 newest of 249 decks. Every deck is listed under its year.
- Q3 2026 Earnings Presentation
Earnings · 153 slides · Oct 30, 2026
- 9M and Q3 2026 Earnings Presentation
Earnings · 46 slides · Oct 30, 2026
- ESMO 2026 Investor Event
Conference · 59 slides · Oct 26, 2026
- ASBMR 2026
Conference · 33 slides · Oct 12, 2026
- Meet AZN Management @ ERS 2026
Conference · 35 slides · Sep 8, 2026